Table 2 Cellular immunogenicity outcomes against wild-type SARS-CoV-2 after the third dose of BNT162b2 in the evaluable analysis population
Adolescents three doses | Adults three doses | |
|---|---|---|
T cell responses | ||
S-specific T cell responses on flow cytometry | ||
N | 26 | 28 |
GM % IFN-γ+CD4+ T cells (95% CI) | 0.058% (0.031–0.111%) | 0.054% (0.027–0.106%) |
% positive (≥cut-off at 0.01%) | 88.5%, P = 0.71 | 82.1% |
GM % IL-2+CD4+ T cells (95% CI) | 0.046% (0.022-0.095%) | 0.040% (0.021–0.075%) |
% positive (≥cut-off at 0.01%) | 80.8%, P > 0.9999 | 78.6% |
GM % IFN-γ+CD8+ T cells (95% CI) | 0.045% (0.023–0.091%) | 0.016% (0.006–0.038%) |
% positive (≥cut-off at 0.01%) | 84.6%, P = 0.002 | 42.9% |
GM % IL-2+CD8+ T cells (95% CI) | 0.027% (0.012–0.059%) | 0.010% (0.005–0.020%) |
% positive (≥cut-off at 0.01%) | 76.9%, P = 0.052 | 50.0% |
% positive with at least 1 cytokine and subset (IFN-γ+/IL-2+CD4/8+) | 100%, P = 0.011 | 85.7% |
